Stock-Based Compensation (Tables)
|
3 Months Ended |
Apr. 30, 2023 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Stock Options Activity |
The following table summarizes the activity related to the Company's stock options: | | | | | | | | | | | | | | | | | | | | | | | | | Outstanding Stock Options | | Weighted-Average Exercise Price | | Weighted-Average Remaining Contractual Life (in years) | | Aggregate Intrinsic Value
(in thousands) | Balance, January 31, 2023 | 4,593,704 | | | $ | 6.45 | | | 3.09 | | $ | 5,020 | | | Granted | — | | | $ | — | | | | | | | Exercised | (1,255,500) | | | $ | 5.77 | | | | | | | Forfeited or canceled | — | | | $ | — | | | | | | Balance, April 30, 2023 | 3,338,204 | | | $ | 6.70 | | | 2.82 | | $ | 8,481 | | | Vested and expected to vest | 3,338,204 | | | $ | 6.70 | | | 2.82 | | $ | 8,481 | | Exercisable at April 30, 2023 | 3,338,204 | | | $ | 6.70 | | | 2.82 | | $ | 8,481 | |
|
| Schedule of Nonvested RSU Activity |
The following table summarizes the activity related to the Company's restricted stock and restricted stock units: | | | | | | | | | | | | | Outstanding | | Weighted-Average Grant Date Fair Value | Balance as of January 31, 2023 | 11,564,867 | | | $ | 8.00 | | | Granted | 529,768 | | | $ | 9.38 | | | Vested and converted to shares | (1,042,572) | | | $ | 10.39 | | | Forfeited or canceled | (855,452) | | | $ | 9.01 | | Balance as of April 30, 2023 | 10,196,611 | | | $ | 7.74 | |
|
| Schedule of Share-Based Compensation Expense |
The Company's stock-based compensation expense for the periods presented was as follows: | | | | | | | | | | | | | | | | | Three months ended April 30, | | (in thousands) | | 2023 | | 2022 | | Cost of revenue | | $ | 644 | | | $ | 1,382 | | | Sales and marketing | | 3,819 | | | 6,376 | | | Research and development | | 2,795 | | | 4,520 | | | General and administrative | | 3,754 | | | 5,808 | | | Total stock-based compensation expense | | $ | 11,012 | | | $ | 18,086 | |
|